What is the Impact Factor of Cns Drugs?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Cns Drugs is 7.00, ranking in quartile Q1 of Web of Science (SCIE).

Is Cns Drugs indexed in Web of Science or Scopus?

Yes, Cns Drugs is indexed in Web of Science (SCIE, Q1 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 2.161 (Q1) and an H-index of 140.

Who publishes Cns Drugs and what is the Article Processing Charge (APC)?

Cns Drugs is published by Springer International Publishing. The estimated Article Processing Charge (APC) is approximately $3,664 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Cns Drugs?

The official ISO-4 abbreviation of Cns Drugs is "CNS DRUGS" with common acronym "cnsa". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q1Scopus Q1SCImago #1,237Top JournalHybrid

Cns Drugs

Acronym:cnsa

•

Abbreviation (ISO):CNS DRUGS

•

Identifier (ISSN):1172-7047(Print)/1179-1934(Online)

•

Publisher:Springer International Publishing

Official Website Submission Portal Compare

Clarivate IF (2026)

7↓ -0.4

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIETop Tier

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Cns Drugs

WoS Q1

Annual Impact Factor Metric

Current (2026):7

Scopus SJR & RankScopus Q1

2.161

#1,237

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

140

140 papers with at least that number of citations each

WoS: SCIE / JCRTop Tier

Self-Citation Rate2.7%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

92articles/year

55.83% Gold OA•53.16% Original Research

Aims & Scope

CNS Drugs promotes rational pharmacotherapy within the disciplines of clinical psychiatry and neurology. The Journal includes: - Overviews of contentious or emerging issues. - Comprehensive narrative reviews that provide an authoritative source of information on pharmacological approaches to managing neurological and psychiatric illnesses. - Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. - Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in neurology and psychiatry. - Original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies. Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in CNS Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.

Topics Covered (Recognized by AI)

Medicine99.8%Biology96.8%Psychology95.2%Psychiatry90.8%Internal medicine84.3%Pharmacology73.6%Neuroscience67.1%Pathology56.6%Chemistry41.6%Biochemistry38.2%Genetics38%Endocrinology35.9%Psychopharmacology34.8%Neurology25.8%Anesthesia25.8%Receptor24.6%Alternative medicine24.3%Surgery22.7%Clinical psychology20.4%Adverse effect20.4%Disease20.1%

Primary Research Areas

Medicine Psychiatry

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

CLINICAL NEUROLOGY

Rank24/296

IndexSCIE

JCRSCIE2026

PHARMACOLOGY & PHARMACY

Rank33/356

IndexSCIE

JCRSCIE2026

PSYCHIATRY

Rank22/293

IndexSCIE

JCISCIE2026

CLINICAL NEUROLOGY

Rank26/296

IndexSCIE

JCISCIE2026

PHARMACOLOGY & PHARMACY

Rank22/356

IndexSCIE

JCISCIE2026

PSYCHIATRY

Rank21/293

IndexSCIE

Category	Index	Rank	Quartile
CLINICAL NEUROLOGY	JCRSCIE	24/296	Q1
PHARMACOLOGY & PHARMACY	JCRSCIE	33/356	Q1
PSYCHIATRY	JCRSCIE	22/293	Q1
CLINICAL NEUROLOGY	JCISCIE	26/296	Q1
PHARMACOLOGY & PHARMACY	JCISCIE	22/356	Q1
PSYCHIATRY	JCISCIE	21/293	Q1

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF7

Articles / Year81

Total Citations48

2025

IF7.4

Articles / Year110

Total Citations656

2024

IF7.4

Articles / Year85

Total Citations1,297

2023

IF6

Articles / Year75

Total Citations1,474

2022

IF6.497

Articles / Year92

Total Citations3,333

Year	Impact Factor	Articles / Year	Total Citations
2026	7	81	48
2025	7.4	110	656
2024	7.4	85	1,297
2023	6	75	1,474
2022	6.497	92	3,333
2021	5.749	109	4,154
2020	4.786	84	3,887
2019	4.192	94	4,582
2018	4.206	109	5,238
2017	—	82	4,764
2016	—	97	5,233
2015	—	80	5,019

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #1,237Scopus Q1SCImago Profile

Scopus Coverage:1994-2026

•

Scopus Broad Areas:Medicine

Scopus Citation Rank (SJR)Q1

2.161

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1

Citations / Doc (2 years)

7.56

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,664 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations1,854

3-Year Documents234

Citable Documents226

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)1

Citations in government and international policy documents

Female Author Rate44.6%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Neurology (clinical)Q1

Pharmacology (medical)Q1

Psychiatry and Mental HealthQ1

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 2.7%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

1区 (Zone 1)Medicine

Minor Category (Specific Field):

1区CLINICAL NEUROLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Cns Drugs (acronym: cnsa, abbr: CNS DRUGS, ISSN: 1172-7047) is a peer-reviewed international scholarly journal in the field of Medicine, published by Springer International Publishing in New Zealand since 1994. The periodical holds a Journal Impact Factor (JIF) of 7.00, ranking in quartile Q1 of Web of Science (SCIE), a Scopus SJR indicator of 2.161 (Q1), an H-index of 140.

The journal enforces rigorous peer evaluation with a publication frequency of Monthly, an annual output of approximately 92 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,664 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.